We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Spinal Surgery Becomes More Cost-Effective Over Time

By HospiMedica International staff writers
Posted on 01 Dec 2011
A new study concludes that for specific causes of back pain, spinal surgery provides a good value (over long-term follow-up) compared to nonsurgical treatment.

Researchers at Dartmouth Medical School (DHMC; Lebanon, NH, USA) analyzed four year follow-up data from the Spine Outcomes Research Trial (SPORT), one of the largest clinical trials of surgery for spinal disorders; 2,427 patients meeting study criteria for degenerative spondylolisthesis (DS, 601 patients), spinal stenosis (SpS, 634 patients), and intervertebral disc herniation (IDH, 1,192 patients), were either randomly assigned to spinal surgery or nonsurgical treatment, or chose their treatment through participation in an observational cohort; in each group, about two-thirds of patients underwent surgery initially or during follow-up. More...
The cost-effectiveness of spinal surgery was calculated by evaluating the costs of treatment versus the benefits gained in quality-adjusted life-years (QALYs).

The results showed after two years, surgery led to significant improvements in health for patients with all three conditions. These benefits persisted through four years' follow-up, although the gains were somewhat greater for patients with DS and IDH than for those with SpS.

Longer follow-up also saw an increase in the value of each procedure as reflected by lower costs per additional QALY gained. The improvement was greatest for patients with DS, with cost per additional QALY gained through surgery decreasing from about USD 115,000 at two years to USD 64,000 at four years. Surgery also became more cost-effective for patients with SpS, from USD 77,000 to USD 59,000 per QALY; and for IDH, reduced from USD 34,000 to USD 20,000 per QALY. The study was published in the November 15, 2011, issue of Spine.

“These data provide a basis for promoting fully informed choice for patients with disc herniation or spinal stenosis with or without degenerative spondylolisthesis who face the difficult decision of whether or not to undergo spine surgery,” concluded lead author Anna Tosteson, ScD, and colleagues at the Dartmouth Institute for Health Policy and Clinical Practice.

Related Links:

Dartmouth Medical School



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.